101 related articles for article (PubMed ID: 8201530)
21. [A comparison of the endocrine effects of hypotension induced by nicardipine with those by sodium nitroprusside in dogs].
Takeda S; Inada Y; Nakamizo N; Nomura N; Tomaru T; Negishi H; Hosoyamada A
Masui; 1991 Jul; 40(7):1063-9. PubMed ID: 1920780
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of the gastrokinetic agent mosapride citrate after intravenous and oral administrations in dogs and monkeys.
Sakashita M; Mizuki Y; Yamaguchi T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Aug; 43(8):864-6. PubMed ID: 8216444
[TBL] [Abstract][Full Text] [Related]
23. A highly potent and long-acting oral inhibitor of human renin.
Hiwada K; Kokubu T; Murakami E; Muneta S; Morisawa Y; Yabe Y; Koike H; Iijima Y
Hypertension; 1988 Jun; 11(6 Pt 2):708-12. PubMed ID: 3134306
[TBL] [Abstract][Full Text] [Related]
24. Orally potent human renin inhibitors derived from angiotensinogen transition state: design, synthesis, and mode of interaction.
Iizuka K; Kamijo T; Harada H; Akahane K; Kubota T; Umeyama H; Ishida T; Kiso Y
J Med Chem; 1990 Oct; 33(10):2707-14. PubMed ID: 2120440
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptidic renin inhibitor A-74273 in dogs.
Wessale JL; Calzadilla SV; Boyd SA; Baker WR; Stein HH; Kovar PJ; Barlow J; Klinghofer V; Mantei R; Kleinert HD
J Cardiovasc Pharmacol; 1993 Oct; 22(4):644-52. PubMed ID: 7505369
[TBL] [Abstract][Full Text] [Related]
26. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
27. Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment.
Fischli W; Clozel JP; Breu V; Buchmann S; Mathews S; Stadler H; Vieira E; Wostl W
Hypertension; 1994 Aug; 24(2):163-9. PubMed ID: 8039839
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetics and efficacy of renin inhibitors.
Rongen GA; Lenders JW; Smits P; Thien T
Clin Pharmacokinet; 1995 Jul; 29(1):6-14. PubMed ID: 7586899
[TBL] [Abstract][Full Text] [Related]
29. ES-8891, an orally active inhibitor of human renin.
Kokubu T; Hiwada K; Murakami E; Muneta S; Kitami Y; Salmon PF
Hypertension; 1990 Jun; 15(6 Pt 2):909-13. PubMed ID: 2112512
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor.
Shibasaki M; Shibasaki K; Ichihara M; Inagaki O; Yanagisawa I; Takenaka T; Murakami K
Eur J Pharmacol; 1994 Dec; 271(2-3):341-8. PubMed ID: 7705434
[TBL] [Abstract][Full Text] [Related]
31. Aldosterone and renin inhibition by physiological levels of atrial natriuretic factor.
Brands MW; Freeman RH
Am J Physiol; 1988 Jun; 254(6 Pt 2):R1011-6. PubMed ID: 2968054
[TBL] [Abstract][Full Text] [Related]
32. Effect of renin inhibitor, ES-8891, on renal renin secretion and storage in the marmoset: comparison with captopril.
Ii Y; Murakami E; Hiwada K
J Hypertens; 1991 Dec; 9(12):1119-25. PubMed ID: 1663967
[TBL] [Abstract][Full Text] [Related]
33. Captopril: pharmacology, metabolism and disposition.
Migdalof BH; Antonaccio MJ; McKinstry DN; Singhvi SM; Lan SJ; Egli P; Kripalani KJ
Drug Metab Rev; 1984; 15(4):841-69. PubMed ID: 6437780
[TBL] [Abstract][Full Text] [Related]
34. Physiological responses to low dose infusions of atrial peptide in conscious dogs.
Metzler CH; Keil LC; Ramsay DJ
Life Sci; 1989; 44(14):935-43. PubMed ID: 2522576
[TBL] [Abstract][Full Text] [Related]
35. Acute hypotensive responses to peptide inhibitors of renin in conscious monkeys: an effect on blood pressure independent of plasma renin inhibition.
Schaffer LW; Schorn TW; Winquist RJ; Strouse JF; Payne L; Chakravarty PK; de Laszlo SE; tenBroeke J; Veber DF; Greenlee WJ
J Hypertens; 1990 Mar; 8(3):251-9. PubMed ID: 2159506
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular effects of YM-16151-4: a novel calcium entry blocking and selective beta 1-adrenoceptor blocking agent in rats and dogs.
Uchida W; Shibasaki K; Matsuda Y; Asano M; Takenaka T
J Cardiovasc Pharmacol; 1993 Aug; 22(2):247-52. PubMed ID: 7692165
[TBL] [Abstract][Full Text] [Related]
37. Evidence that the renin decrease during hypoxia is adenosine mediated in conscious dogs.
Höhne C; Krebs MO; Boemke W; Arntz E; Kaczmarczyk G
J Appl Physiol (1985); 2001 May; 90(5):1842-8. PubMed ID: 11299275
[TBL] [Abstract][Full Text] [Related]
38. Acute effects of a pseudo-tetrapeptide as renin inhibitor on blood pressure and renin-angiotensin system of sodium-repleted and sodium-depleted hypertensive patients.
Denolle T; Luo P; Guyene TT; Cazaubon C; Sissmann J; Corvol P; Ménard J
Arzneimittelforschung; 1993 Feb; 43(2A):255-9. PubMed ID: 8498973
[TBL] [Abstract][Full Text] [Related]
39. Kidney renin gene expression after renin inhibition in the marmoset.
Kitami Y; Hiwada K; Murakami E; Iwata T; Muneta S; Kokubu T
Clin Sci (Lond); 1991 Sep; 81(3):387-92. PubMed ID: 1655341
[TBL] [Abstract][Full Text] [Related]
40. Human renin inhibiting dipeptide.
Toda N; Miyazaki M; Etoh Y; Kubota T; Iizuka K
Eur J Pharmacol; 1986 Oct; 129(3):393-6. PubMed ID: 3536533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
